The combined administration of anti-NKG2A and anti-PD-L1 blocking antibodies unleashes NK and CD8+ T cells and subsequently slows tumor progression in mouse models and preliminary analyses suggest in vivo efficacy of Monalizumab when in combination with the EGF receptor (EGFR) blockade antibody (Cetuximab) in recurrent/metastatic squamous cell carcinoma of the head and neck (HNSCC) (30). This evidence concerns the gene CD8A and neoplasm.